In adults with extensive-stage small cell lung cancer (ES-SCLC) after the first course of therapy has worked to help stop it from getting worse

Maintenance therapy: Clinical results with
ZEPZELCA + atezolizumab

After your first course of therapy with carboplatin, etoposide, and atezolizumab has helped shrink tumors or slowed the progression of ES-SCLC, you may receive ZEPZELCA with atezolizumab as maintenance therapy. Maintenance therapy can help keep your ES-SCLC under control.

Illustration of two men walking with a child holding a balloon.

As shown in a Phase 3 clinical trial, ZEPZELCA + atezolizumab is the first and only maintenance therapy proven to help people with ES-SCLC live longer, making it an important treatment option that your doctor may recommend.

In a clinical trial, people were treated with ZEPZELCA + atezolizumab or with atezolizumab as maintenance therapy

This trial included an initial phase, in which people received 4 cycles of therapy with atezolizumab + chemotherapy (carboplatin and etoposide). Patients who responded to the initial treatment showing no progression went into the maintenance phase, in which 242 people were treated with ZEPZELCA + atezolizumab and 241 people were treated with atezolizumab.

Median overall survival*

13.2 months on ZEPZELCA + atezolizumab

10.6 monthson atezolizumab

*Median overall survival means the midpoint between people who lived the longest and those who lived for the shortest period of time.

Illustration of two men walking with a child holding a balloon.

Together, ZEPZELCA + atezolizumab may help control your cancer and help you live longer.

Doctor Discussion Guide

The Doctor Discussion Guide is a resource that will help you talk to your doctor so that you can understand ZEPZELCA + atezolizumab as a maintenance therapy.

Download in English Download in Spanish

Side Effects

Explore the possible side effects of ZEPZELCA + atezolizumab.

Learn more

What is ZEPZELCA (lurbinectedin) for injection 4 mg?

ZEPZELCA may be used to treat adults with a kind of lung cancer called small cell lung cancer (SCLC):

ZEPZELCA may be used in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs as maintenance treatment when your lung cancer:
- is a type called “extensive-stage,” which means it has spread or grown, and
- has not progressed after first treatment with atezolizumab or atezolizumab and hyaluronidase-tqjs and the chemotherapy medicines carboplatin and etoposide.
ZEPZELCA may be used when your lung cancer:
- has spread to other parts of the body (metastatic), and
- you have received treatment with chemotherapy that contains platinum, and it did not work or is no longer working.
ZEPZELCA is approved based on response rate and how long the response lasted. Additional studies will further evaluate the benefit of ZEPZELCA for this use.

It is not known if ZEPZELCA is safe and effective in children.

Please see full Prescribing Information, including Patient Information, and discuss with your doctor.

IMPORTANT SAFETY INFORMATION

Before receiving ZEPZELCA, tell your healthcare provider about all of your medical conditions, including if you:

have liver or kidney problems.
are pregnant or plan to become pregnant. ZEPZELCA can harm your unborn baby.
Females who are able to become pregnant:
- Your healthcare provider should do a pregnancy test before you start treatment with ZEPZELCA.
- You should use effective birth control (contraception) during treatment with and for 6 months after your last dose of ZEPZELCA.
- Tell your healthcare provider right away if you become pregnant or think that you are pregnant during treatment with ZEPZELCA.
Males with female partners who are able to become pregnant should use effective birth control during treatment with and for 4 months after your last dose of ZEPZELCA.
are breastfeeding or plan to breastfeed. It is not known if ZEPZELCA passes into your breastmilk. Do not breastfeed during treatment with ZEPZELCA and for 2 weeks after your last dose of ZEPZELCA. Talk to your healthcare provider about the best way to feed your baby during treatment with ZEPZELCA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain other medicines may affect how ZEPZELCA works.

What should I avoid while using ZEPZELCA?

Avoid eating or drinking grapefruit, Seville oranges, or products that contain grapefruit juice and Seville oranges during treatment with ZEPZELCA.

ZEPZELCA can cause serious side effects, including:

Low blood cell counts. Low blood counts including low neutrophil counts (neutropenia) and low platelet counts (thrombocytopenia) are common with ZEPZELCA, and can also be severe. Some people with low white blood cell counts may get fever, or an infection throughout the body (sepsis), that can cause death. Your healthcare provider should do blood tests before you receive each treatment with ZEPZELCA to check your blood cell counts.
Tell your healthcare provider right away if you develop:
- fever or any other signs of infection
- unusual bruising or bleeding
- tiredness
- pale colored skin

Liver problems. Increased liver function tests are common with ZEPZELCA and can also be severe. Your healthcare provider should do blood tests to check your liver function before you start and during treatment with ZEPZELCA.
Tell your healthcare provider right away if you develop symptoms of liver problems including:
- loss of appetite
- nausea or vomiting
- pain on the right side of your stomach area (abdomen)

Skin damage at or near the infusion site. ZEPZELCA can cause damage and death of tissue cells if it leaks into the tissues around your infusion site. You may need to have surgery to remove any dead tissue. Tell your healthcare provider right away if you see any fluid leaking at or around the catheter during your infusion, or if you notice any redness, swelling, itching or discomfort at the infusion site at any time.

Severe muscle problems (rhabdomyolysis). Treatment with ZEPZELCA may increase the level of an enzyme in your blood called creatine phosphokinase (CPK). Your healthcare provider should do blood tests to check your CPK levels before you start and during treatment with ZEPZELCA. Tell your healthcare provider if you have severe muscle pain or weakness.

Your healthcare provider may temporarily stop treatment, lower your dose, or permanently stop ZEPZELCA if you develop serious side effects during treatment with ZEPZELCA.

The most common side effects of ZEPZELCA given alone include:

tiredness
low level of albumin in the blood
low white and red blood cell counts
constipation
increased kidney function blood test (creatinine)
trouble breathing
increased liver function blood tests
low levels of sodium and magnesium in the blood
increased blood sugar (glucose)
vomiting
nausea
cough
decreased appetite
diarrhea
muscle and joint (musculoskeletal) pain

tiredness
low white and red blood cell counts
increased kidney function blood test (creatinine)
increased liver function blood tests
increased blood sugar (glucose)
nausea
decreased appetite
muscle and joint (musculoskeletal) pain
low level of albumin in the blood
constipation
trouble breathing
low levels of sodium and magnesium in the blood
vomiting
cough
diarrhea

The most common side effects of ZEPZELCA given with atezolizumab include:

low white and red blood cell counts
nausea
tiredness or weakness

These are not all of the possible side effects of ZEPZELCA.

Call your doctor for medical advice about side effects. You are encouraged to report suspected side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Jazz Pharmaceuticals at 1-800-520-5568.

Please see full Prescribing Information, including Patient Information, and discuss with your doctor.

What is ZEPZELCA (lurbinectedin) for injection 4 mg?

ZEPZELCA may be used to treat adults with a kind of lung cancer called small cell lung cancer (SCLC):

ZEPZELCA may be used in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs as maintenance treatment when your lung cancer:
- is a type called “extensive-stage,” which means it has spread or grown, and
- has not progressed after first treatment with atezolizumab or atezolizumab and hyaluronidase-tqjs and the chemotherapy medicines carboplatin and etoposide.
ZEPZELCA may be used when your lung cancer:
- has spread to other parts of the body (metastatic), and
- you have received treatment with chemotherapy that contains platinum, and it did not work or is no longer working.
ZEPZELCA is approved based on response rate and how long the response lasted. Additional studies will further evaluate the benefit of ZEPZELCA for this use.

It is not known if ZEPZELCA is safe and effective in children.

Please see full Prescribing Information, including Patient Information, and discuss with your doctor.

IMPORTANT SAFETY INFORMATION

Before receiving ZEPZELCA, tell your healthcare provider about all of your medical conditions, including if you:

have liver or kidney problems.
are pregnant or plan to become pregnant. ZEPZELCA can harm your unborn baby.
Females who are able to become pregnant:
- Your healthcare provider should do a pregnancy test before you start treatment with ZEPZELCA.
- You should use effective birth control (contraception) during treatment with and for 6 months after your last dose of ZEPZELCA.
- Tell your healthcare provider right away if you become pregnant or think that you are pregnant during treatment with ZEPZELCA.
Males with female partners who are able to become pregnant should use effective birth control during treatment with and for 4 months after your last dose of ZEPZELCA.
are breastfeeding or plan to breastfeed. It is not known if ZEPZELCA passes into your breastmilk. Do not breastfeed during treatment with ZEPZELCA and for 2 weeks after your last dose of ZEPZELCA. Talk to your healthcare provider about the best way to feed your baby during treatment with ZEPZELCA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain other medicines may affect how ZEPZELCA works.

What should I avoid while using ZEPZELCA?

Avoid eating or drinking grapefruit, Seville oranges, or products that contain grapefruit juice and Seville oranges during treatment with ZEPZELCA.

ZEPZELCA can cause serious side effects, including:

Low blood cell counts. Low blood counts including low neutrophil counts (neutropenia) and low platelet counts (thrombocytopenia) are common with ZEPZELCA, and can also be severe. Some people with low white blood cell counts may get fever, or an infection throughout the body (sepsis), that can cause death. Your healthcare provider should do blood tests before you receive each treatment with ZEPZELCA to check your blood cell counts.
Tell your healthcare provider right away if you develop:
- fever or any other signs of infection
- unusual bruising or bleeding
- tiredness
- pale colored skin

Liver problems. Increased liver function tests are common with ZEPZELCA and can also be severe. Your healthcare provider should do blood tests to check your liver function before you start and during treatment with ZEPZELCA.
Tell your healthcare provider right away if you develop symptoms of liver problems including:
- loss of appetite
- nausea or vomiting
- pain on the right side of your stomach area (abdomen)

Skin damage at or near the infusion site. ZEPZELCA can cause damage and death of tissue cells if it leaks into the tissues around your infusion site. You may need to have surgery to remove any dead tissue. Tell your healthcare provider right away if you see any fluid leaking at or around the catheter during your infusion, or if you notice any redness, swelling, itching or discomfort at the infusion site at any time.

Severe muscle problems (rhabdomyolysis). Treatment with ZEPZELCA may increase the level of an enzyme in your blood called creatine phosphokinase (CPK). Your healthcare provider should do blood tests to check your CPK levels before you start and during treatment with ZEPZELCA. Tell your healthcare provider if you have severe muscle pain or weakness.

Your healthcare provider may temporarily stop treatment, lower your dose, or permanently stop ZEPZELCA if you develop serious side effects during treatment with ZEPZELCA.

The most common side effects of ZEPZELCA given alone include:

tiredness
low level of albumin in the blood
low white and red blood cell counts
constipation
increased kidney function blood test (creatinine)
trouble breathing
increased liver function blood tests
low levels of sodium and magnesium in the blood
increased blood sugar (glucose)
vomiting
nausea
cough
decreased appetite
diarrhea
muscle and joint (musculoskeletal) pain

tiredness
low white and red blood cell counts
increased kidney function blood test (creatinine)
increased liver function blood tests
increased blood sugar (glucose)
nausea
decreased appetite
muscle and joint (musculoskeletal) pain
low level of albumin in the blood
constipation
trouble breathing
low levels of sodium and magnesium in the blood
vomiting
cough
diarrhea

The most common side effects of ZEPZELCA given with atezolizumab include:

low white and red blood cell counts
nausea
tiredness or weakness

These are not all of the possible side effects of ZEPZELCA.

Call your doctor for medical advice about side effects. You are encouraged to report suspected side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Jazz Pharmaceuticals at 1-800-520-5568.

Please see full Prescribing Information, including Patient Information, and discuss with your doctor.